Cemiplimab-rwlc has been approved by the FDA for the treatment of locally progressed and metastatic basal cell carcinoma

Share This Post

August 20, 2021: The FDA has given cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) regular approval for patients with locally advanced basal cell carcinoma (laBCC) who have previously been treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate, as well as accelerated approval for patients with metastatic BCC (mBCC) who have previously been treated with an HH.

Patients with advanced BCC (laBCC or mBCC) who had progressed on HHI therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant to prior HHI therapy were investigated in Study 1620 (NCT03132636), an ongoing open-label, multi-center, non-randomized experiment. A multidisciplinary examination determined that laBCC patients were not candidates for curative surgery or curative RT. Cemiplimab-rwlc 350 mg was given to all patients every 3 weeks for up to 93 weeks, or until disease progression, intolerable toxicity, or the end of the treatment regimen.

Confirmed objective response rate (ORR) and duration of response (DOR) were the primary efficacy outcome measures, as determined by an independent central review. Confirmed ORR was determined using RECIST 1.1 for patients with no externally evident target lesions (mBCC). For individuals with externally visible target lesions, a composite response assessment comprising clinical response criteria utilising digital medical photography and RECIST 1.1 was used (laBCC and mBCC).

The confirmed ORR was 29% (95 percent CI: 19, 40) among 84 patients with laBCC, with a median DOR of not attained (range: 2.1 to 21.4+ months) and 79 percent of responders continuing their response for at least 6 months. The verified ORR was 21% (95 percent CI: 8, 41) among 28 patients with mBCC, with a median DOR of not attained (range: 9 to 23.0+ months) and all responders maintained their responses for at least 6 months.

Immune-mediated adverse reactions (e.g., pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus, and nephritis) and infusion reactions are examples of severe adverse reactions. Fatigue, musculoskeletal pain, diarrhoea, rash, and pruritis were the most prevalent side effects (incidence 20%).

Cemiplimab-rwlc is given as a 350 mg intravenous infusion over 30 minutes every three weeks until disease progression or intolerable toxicity occurs.

Reference : https://www.fda.gov/


Check details here.

Take second opinion on basal cell carcinoma

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form